Akademik Veri Yönetim Sistemi
BJU International, 2026 (SCI-Expanded, Scopus)
Objective: To assess the efficacy and safety of low-intensity shockwave therapy (LiSWT) for treating erectile dysfunction (ED) compared to sham therapy. Methods: This summary is based on the Cochrane systematic review published in the Cochrane Database of Systematic Reviews 2025, Issue 7 (CD013166). We included randomised controlled trials (RCTs) comparing LiSWT to sham therapy. We excluded psychogenic or iatrogenic ED, kidney transplants, or radical prostatectomy. Critical outcomes were erectile function, discontinuation, and adverse events; important outcomes included rigidity, satisfaction, and quality of life. Certainty was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. Results: A total of 21 RCTs (1357 men, aged 39–65 years) were analysed. LiSWT may slightly improve short-term erectile function (mean difference [MD] 3.89, 95% confidence interval [CI] 2.89–4.89; I2 = 62%; 15 studies; low-certainty), though clinical importance is uncertain. Long-term function may improve (MD 5.25, 95% CI 2.47–8.04; I2 = 87%; five studies; low-certainty). LiSWT likely has little effect on discontinuation (risk ratio 0.77, 95% CI 0.47–1.27; I2 = 0%) or adverse events (risk difference 0.00, 95% CI −0.01 to 0.02; I2 = 0%). It may improve short-term penile rigidity (MD 1.06, 95% CI 0.83–1.28; I2 = 53%; low-certainty). Data for satisfaction or quality of life were unavailable. Conclusions: Low-intensity shockwave therapy may improve long-term erectile function and short-term rigidity, with little difference in discontinuation or adverse events. Evidence certainty is low due to methodological limitations and heterogeneity.